Switzerland

Basilea Pharmaceutica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Basilea Announces Completion of Patient Enrolment into First Cohort of Phase 2 Study FIDES-01 With Derazantinib

Lead Product(s): Derazantinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

The FIDES-01 study is a multi-center, open-label phase 2 registrational study of once-daily oral derazantinib for the treatment of patients with inoperable or advanced iCCA and FGFR2 gene fusions or FGFR2 gene mutations or amplifications.

ADC Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ADC Therapeutics Announces U.S FDA has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

Lead Product(s): Camidanlumab Tesirine

Therapeutic Area: Oncology Product Name: ADCT-301

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).

ADC Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ADC Therapeutics Reports Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine

Lead Product(s): Loncastuximab Tesirine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2020

Details:

Interim results of the Phase 1/2 trial of Lonca in combination with ibrutinib show an encouraging overall response rate of 75.0% and complete response rate of 58.3% at the recommended Phase 2 Lonca dose.

ADC Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine Trial Data Being Presented at Virtual EHA Annual Congress

Lead Product(s): Loncastuximab Tesirine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Updated interim data from the pivotal Phase 2 trial of Lonca in patients with relapsed or refactory diffuse large B-cell lymphoma as well as interim results of a Phase 1/2 trial highlighting the potential to advance Lonca into earlier lines of therapy in combination therapies.

ADC Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

Lead Product(s): Loncastuximab Tesirine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma.

Helsinn

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine

Lead Product(s): Pracinostat,Azacitidine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

New data from the Phase 2 study evaluating pracinostat in combination with azacitidine in patients with very-high risk myelodysplastic syndromes, will be featured in the ASCO 2020 conference.

ADC Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans

Lead Product(s): Loncastuximab Tesirine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 28, 2020

Details:

ADC Therapeutics company is developing antibody drug conjugates, cancer drugs that link a tumor-targeting antibody to a cancer-killing chemical compound.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Novartis' Capmatinib Tackles Brain Cancer

Lead Product(s): Capmatinib Hydrochloride

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

In a phase 2 study to be presented virtually at the American Association for Cancer Research meeting, capmatinib controlled disease in the brain in 12 of 13 evaluable patients with brain metastases.

Sellas Life Sciences Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women

Lead Product(s): Nelipepimut-S,Sargramostim

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Novartis pulls ahead of Merck in MET-positive lung cancer race

Lead Product(s): Capmatinib Hydrochloride

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 11, 2020

Details:

Capmatinib has been submitted for approval in the US for metastatic MET exon14 skipping-mutated NSCLC.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Basilea Pharmaceutica

Basilea Announces Completion of Patient Enrolment into First Cohort of Phase 2 Study FIDES-01 With Derazantinib

ADC Therapeutics

ADC Therapeutics Announces U.S FDA has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

ADC Therapeutics

ADC Therapeutics Reports Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine

ADC Therapeutics

ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine Trial Data Being Presented at Virtual EHA Annual Congress

ADC Therapeutics

ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

Helsinn

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine

ADC Therapeutics

ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans

Novartis Pharmaceuticals Corporation

Novartis' Capmatinib Tackles Brain Cancer

Sellas Life Sciences Group

SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women

Novartis Pharmaceuticals Corporation

Novartis pulls ahead of Merck in MET-positive lung cancer race